Literature DB >> 29031806

Tumor suppressive protein phosphatases in human cancer: Emerging targets for therapeutic intervention and tumor stratification.

Bob Meeusen1, Veerle Janssens2.   

Abstract

Aberrant protein phosphorylation is one of the hallmarks of cancer cells, and in many cases a prerequisite to sustain tumor development and progression. Like protein kinases, protein phosphatases are key regulators of cell signaling. However, their contribution to aberrant signaling in cancer cells is overall less well appreciated, and therefore, their clinical potential remains largely unexploited. In this review, we provide an overview of tumor suppressive protein phosphatases in human cancer. Along their mechanisms of inactivation in defined cancer contexts, we give an overview of their functional roles in diverse signaling pathways that contribute to their tumor suppressive abilities. Finally, we discuss their emerging roles as predictive or prognostic markers, their potential as synthetic lethality targets, and the current feasibility of their reactivation with pharmacologic compounds as promising new cancer therapies. We conclude that their inclusion in clinical practice has obvious potential to significantly improve therapeutic outcome in various ways, and should now definitely be pushed forward.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACPP; DUSP; ILKAP; PDP; PHLPP; PP2A; PPM; PTPN; PTPR; Phosphatase reactivation therapy; Predictive marker; Prognostic marker; Protein phosphatase; Synthetic lethality; Tumor suppressor

Mesh:

Substances:

Year:  2017        PMID: 29031806     DOI: 10.1016/j.biocel.2017.10.002

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  24 in total

Review 1.  Targeting PP2A in cancer: Combination therapies.

Authors:  Sahar Mazhar; Sarah E Taylor; Jaya Sangodkar; Goutham Narla
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2018-09-01       Impact factor: 4.739

2.  Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1.

Authors:  Otto Kauko; Susumu Y Imanishi; Evgeny Kulesskiy; Laxman Yetukuri; Teemu Daniel Laajala; Mukund Sharma; Karolina Pavic; Anna Aakula; Christian Rupp; Mikael Jumppanen; Pekka Haapaniemi; Luyao Ruan; Bhagwan Yadav; Veronika Suni; Taru Varila; Garry L Corthals; Jüri Reimand; Krister Wennerberg; Tero Aittokallio; Jukka Westermarck
Journal:  J Biol Chem       Date:  2020-02-18       Impact factor: 5.157

3.  PP2A Inhibits Cervical Cancer Cell Migration by Dephosphorylation of p-JNK, p-p38 and the p-ERK/MAPK Signaling Pathway.

Authors:  Hong-Yun Zheng; Fu-Jin Shen; Yong-Qing Tong; Yan Li
Journal:  Curr Med Sci       Date:  2018-03-15

4.  PP2A is a therapeutically targetable driver of cell fate decisions via a c-Myc/p21 axis in human and murine acute myeloid leukemia.

Authors:  Swagata Goswami; Rajeswaran Mani; Jessica Nunes; Chi-Ling Chiang; Kevan Zapolnik; Eileen Hu; Frank Frissora; Xiaokui Mo; Logan A Walker; Pearlly Yan; Ralf Bundschuh; Larry Beaver; Raymond Devine; Yo-Ting Tsai; Ann Ventura; Zhiliang Xie; Min Chen; Rosa Lapalombella; Alison Walker; Alice Mims; Karilyn Larkin; Nicole Grieselhuber; Chad Bennett; Mitch Phelps; Erin Hertlein; Gregory Behbehani; Sumithira Vasu; John C Byrd; Natarajan Muthusamy
Journal:  Blood       Date:  2022-03-03       Impact factor: 25.476

5.  Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246-Sensitive Disease Subtype.

Authors:  Anna N Cvrljevic; Umar Butt; Kaisa Huhtinen; Tove J Grönroos; Camilla Böckelman; Heini Lassus; Ralf Butzow; Caj Haglund; Katja Kaipio; Tiina Arsiola; Teemu D Laajala; Denise C Connolly; Ari Ristimäki; Olli Carpen; Jeroen Pouwels; Jukka Westermarck
Journal:  Mol Cancer Ther       Date:  2022-07-05       Impact factor: 6.009

Review 6.  The impact of phosphatases on proliferative and survival signaling in cancer.

Authors:  Goutham Narla; Jaya Sangodkar; Christopher B Ryder
Journal:  Cell Mol Life Sci       Date:  2018-05-03       Impact factor: 9.261

7.  Differential Proteomic Analysis of Hepatocellular Carcinomas from Ppp2r5d Knockout Mice and Normal (Knockout) Livers.

Authors:  Caroline Lambrecht; Gabriela Bomfim Ferreira; Judit DomÈnech Omella; Louis Libbrecht; Rita DE Vos; Rita Derua; Chantal Mathieu; Lut Overbergh; Etienne Waelkens; Veerle Janssens
Journal:  Cancer Genomics Proteomics       Date:  2020 Nov-Dec       Impact factor: 4.069

8.  A general calculus of fitness landscapes finds genes under selection in cancers.

Authors:  Teng-Kuei Hsu; Jennifer Asmussen; Amanda Koire; Byung-Kwon Choi; Mayur A Gadhikar; Eunna Huh; Chih-Hsu Lin; Daniel M Konecki; Young Won Kim; Curtis R Pickering; Marek Kimmel; Lawrence A Donehower; Mitchell J Frederick; Jeffrey N Myers; Panagiotis Katsonis; Olivier Lichtarge
Journal:  Genome Res       Date:  2022-03-17       Impact factor: 9.438

Review 9.  Targeted Therapies in Type II Endometrial Cancers: Too Little, but Not Too Late.

Authors:  Michiel Remmerie; Veerle Janssens
Journal:  Int J Mol Sci       Date:  2018-08-13       Impact factor: 5.923

10.  The Cell Cycle Checkpoint System MAST(L)-ENSA/ARPP19-PP2A is Targeted by cAMP/PKA and cGMP/PKG in Anucleate Human Platelets.

Authors:  Elena J Kumm; Oliver Pagel; Stepan Gambaryan; Ulrich Walter; René P Zahedi; Albert Smolenski; Kerstin Jurk
Journal:  Cells       Date:  2020-02-18       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.